IDEAYA Biosciences (IDYA) News Today → Trump’s Former Wingman Bets Big on AI (From Banyan Hill Publishing) (Ad) Free IDYA Stock Alerts $41.80 +0.73 (+1.78%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 12:29 PM | marketbeat.comThe Goldman Sachs Group Cuts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $46.00The Goldman Sachs Group decreased their price target on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Monday.May 12 at 4:48 AM | marketbeat.comVictory Capital Management Inc. Takes Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Victory Capital Management Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 346,490 shares of the company's stock, valued at approximatelMay 11, 2024 | americanbankingnews.comWedbush Research Analysts Increase Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 11, 2024 | americanbankingnews.comLeerink Partnrs Comments on IDEAYA Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:IDYA)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline CatalystsMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Decreased by Leerink PartnrsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now expects tMay 10, 2024 | marketbeat.comNew York State Common Retirement Fund Boosts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)New York State Common Retirement Fund lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 98.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,657 shaMay 10, 2024 | americanbankingnews.comQ1 2025 Earnings Forecast for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Issued By WedbushMay 9, 2024 | marketbeat.comIDEAYA Biosciences, Inc. to Post Q1 2025 Earnings of ($0.72) Per Share, Wedbush Forecasts (NASDAQ:IDYA)IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.72) for thMay 8, 2024 | markets.businessinsider.comUnveiling 5 Analyst Insights On IDEAYA BiosciencesMay 8, 2024 | finance.yahoo.comIDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)May 8, 2024 | marketbeat.comIDEAYA Biosciences' (IDYA) "Outperform" Rating Reiterated at WedbushWedbush reiterated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday.May 8, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPSIDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The company's revenue was down 100.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.49) earnings per share.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: IDEAYA Biosciences’ Promising Pipeline and Strong Financial PositionMay 7, 2024 | investorplace.comIDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comIDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 7, 2024 | prnewswire.comIDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | marketbeat.comFisher Asset Management LLC Buys 507,500 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Fisher Asset Management LLC raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 1,609.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 539,025 shares of the compaMay 5, 2024 | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Buy" by AnalystsMay 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventApril 26, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyApril 22, 2024 | prnewswire.comIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerApril 18, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Trading Down 3.2%IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.2%April 18, 2024 | marketbeat.comFederated Hermes Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Federated Hermes Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,883,775 shares of the company's stocApril 16, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Short Interest Up 6.7% in MarchIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Currently, 14.3% of the company's stock are short sold. Based on an average daily volume of 905,000 shares, the short-interest ratio is currently 10.4 days.April 10, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Buy" by AnalystsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has received a consensus recommendation of "Buy" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports. Thirteen analysts have rated the stock with a buy recommendation. The average 12 month price targeApril 6, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Vanguard Group Inc. lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,971,497 shares of the company's stock after purchasing an additional 141,844 shares during the peApril 5, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventMarch 21, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $60.00 at CitigroupCitigroup boosted their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday.March 20, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IDYAMarch 17, 2024 | marketbeat.comHudson Bay Capital Management LP Takes $944,000 Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Hudson Bay Capital Management LP acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 35,000 shares of the company's stMarch 13, 2024 | markets.businessinsider.comStrong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology PipelineMarch 12, 2024 | msn.comIdeaya gains after clinical trial pact with MerckMarch 12, 2024 | seekingalpha.comIdeaya inks clinical trial pact with MerckMarch 12, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Trading Up 3.3%IDEAYA Biosciences (NASDAQ:IDYA) Trading Up 3.3%March 12, 2024 | markets.businessinsider.comIDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial CancerMarch 12, 2024 | prnewswire.comIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerMarch 11, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 35,489 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Schonfeld Strategic Advisors LLC lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 51.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,848 shares of the company's stock after selling 35,489March 10, 2024 | benzinga.comIDEAYA Biosciences Stock (NASDAQ:IDYA), Quotes and News SummaryMarch 10, 2024 | marketbeat.comTrexquant Investment LP Cuts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Trexquant Investment LP decreased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 67.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,552 sharesMarch 9, 2024 | marketbeat.comInvesco Ltd. Has $7.83 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Invesco Ltd. lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 26.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 290,267 shares of the company's stock after buying an additional 61,157 shares duMarch 8, 2024 | markets.businessinsider.comDemystifying IDEAYA Biosciences: Insights From 6 Analyst ReviewsMarch 8, 2024 | marketbeat.comBTIG Research Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)BTIG Research initiated coverage on IDEAYA Biosciences in a research note on Friday. They set a "buy" rating and a $55.00 price target on the stock.March 5, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 288,149 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Adage Capital Partners GP L.L.C. reduced its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 11.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,286,961 shares of the company's stock after selling 288March 4, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations EventsMarch 1, 2024 | marketbeat.comEventide Asset Management LLC Makes New Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Eventide Asset Management LLC purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 335,000 shares of the company's stock, valued at approximately $9,0February 28, 2024 | marketbeat.comBoone Capital Management LLC Acquires 74,249 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Boone Capital Management LLC lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 15.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 570,682 shares of the coFebruary 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD) Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Former Wingman Bets Big on AI (Ad)One of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information. Get the full story here. IDYA Media Mentions By Week IDYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.240.56▲Average Medical News Sentiment IDYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼273▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Xenon Pharmaceuticals News Summit Therapeutics News Biohaven News Ultragenyx Pharmaceutical News Corcept Therapeutics News Arrowhead Pharmaceuticals News Prestige Consumer Healthcare News TG Therapeutics News MorphoSys News Avidity Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Crypto 9-5 Escape PlanCrypto 101 MediaRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
